364 related articles for article (PubMed ID: 8039761)
1. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
[TBL] [Abstract][Full Text] [Related]
2. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
[TBL] [Abstract][Full Text] [Related]
3. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Appel IM; Hop WC; Pieters R
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):139-46. PubMed ID: 16479196
[TBL] [Abstract][Full Text] [Related]
4. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study.
Leone G; Gugliotta L; Mazzucconi MG; De Stefano V; Belmonte MM; Dragoni F; Specchia G; Centra A; Gamba G; Camera A
Thromb Haemost; 1993 Jan; 69(1):12-5. PubMed ID: 8446931
[TBL] [Abstract][Full Text] [Related]
5. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
[TBL] [Abstract][Full Text] [Related]
6. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Ruud E; Holmstrøm H; de Lange C; Natvig S; Albertsen BK; Wesenberg F
Pediatr Hematol Oncol; 2006; 23(3):207-16. PubMed ID: 16517537
[TBL] [Abstract][Full Text] [Related]
9. Negligible hemostatic toxicity of intermediate-dose Erwinase in adult patients with acute lymphoblastic leukemia: preliminary data.
Nocentini F; Gugliotta L; Catani L; Vianelli N; Baravelli S; Martelli V; Tura S
Haematologica; 1994; 79(6):546-9. PubMed ID: 7896215
[TBL] [Abstract][Full Text] [Related]
10. [Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols].
Sutor AH; Niemeyer C; Sauter S; Witt I; Kaufmehl K; Rombach A; Brandis M; Riehm H
Klin Padiatr; 1992; 204(4):264-73. PubMed ID: 1518263
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia.
Castaman G; Rodeghiero F; Dini E
Haematologica; 1990; 75(6):567-9. PubMed ID: 2098299
[TBL] [Abstract][Full Text] [Related]
12. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
[TBL] [Abstract][Full Text] [Related]
13. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
Klug Albertsen B; Schmiegelow K; Schrøder H; Carlsen NT; Rosthøj S; Avramis VI; Jakobsen P
Cancer Chemother Pharmacol; 2002 Aug; 50(2):117-20. PubMed ID: 12172975
[TBL] [Abstract][Full Text] [Related]
14. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia.
Beinart G; Damon L
Am J Hematol; 2004 Dec; 77(4):331-5. PubMed ID: 15551293
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of asparaginase-induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation.
Ridgway D; Neerhout RC; Bleyer A
Cancer; 1989 Feb; 63(3):561-3. PubMed ID: 2643458
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
18. [Effect of E coli or Erwinia asparaginase and corticotherapy on fibrinogen concentration in induction of acute lymphoblastic leukemia in children].
Astruc D; Nowak V; Grunebaum L; Wiesel ML; Cazenave JP; Babin-Boilletot A; Lutz P
Arch Pediatr; 1994 Jun; 1(6):617-8. PubMed ID: 7994359
[No Abstract] [Full Text] [Related]
19. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase.
Mattioli Belmonte M; Gugliotta L; Delvos U; Catani L; Vianelli N; Cascione ML; Belardinelli AR; Mottola L; Tura S
Haematologica; 1991; 76(3):209-14. PubMed ID: 1743591
[TBL] [Abstract][Full Text] [Related]
20. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia.
Mitchell LG; Halton JM; Vegh PA; Barr RD; Venneri T; Pai KM; Andrew ME
Am J Pediatr Hematol Oncol; 1994 May; 16(2):120-6. PubMed ID: 8166364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
